Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy

This study will evaluate the efficacy and safety of antharcycline-based adjuvant chemotherapy compared with observation in triple negative breast cancer (TNBC) patients with residual invasive disease after platinum and taxanes based neoadjuvant chemotherapy.

Trial Details

NCT ID

NCT04437160

Phase

PHASE2

Sponsor

Chinese Academy of Medical Sciences

Status

RECRUITING

Cancer Type

Triple Negative (TNBC) Breast Cancer

Interventions

Epirubicin or Pirarubicin
Cyclophosphamide

Locations (sample)

Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

Patients with histologically confirmed invasive adenocarcinoma of the breast.
Triple negative breast cancer: hormone receptor negative (ER \< 10% and PgR \< 10%) and HER2 negative (IHC 0/1+ or ISH non-amplified), as defined b…
Clinical stage at presentation: T1-4, N0-3, M0, with indications for neoadjuvant chemotherapy.
Patient must have received platinum and taxanes neoadjuvant chemotherapy for at least 4 cycles and no tumor progression occurred.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Triple Negative (TNBC) Breast Cancer Trials on Trialify →